Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Roeker LE, Feldman TA, Soumerai JD, Falco V, Panton G, Dorsey C, Zelenetz AD, Falchi L, Park JH, Straus DJ, Pena Velasquez C, Lebowitz S, Fox Y, Battiato K, Laudati C, Thompson MC, McCarthy E, Kdiry S, Martignetti R, Turpuseema T, Purdom M, Paskalis D, Miskin HP, Sportelli P, Leslie LA, Mato AR. Roeker LE, et al. Among authors: park jh. Clin Cancer Res. 2022 Sep 15;28(18):3958-3964. doi: 10.1158/1078-0432.CCR-22-0964. Clin Cancer Res. 2022. PMID: 35852793 Free PMC article. Clinical Trial.
Targeted immunotherapy for hairy cell leukemia.
Park JH, Levine RL. Park JH, et al. J Clin Oncol. 2012 May 20;30(15):1888-90. doi: 10.1200/JCO.2011.39.8313. Epub 2012 Feb 21. J Clin Oncol. 2012. PMID: 22355051 No abstract available.
Immunotherapies in CLL.
Park JH, Brentjens RJ. Park JH, et al. Adv Exp Med Biol. 2013;792:241-57. doi: 10.1007/978-1-4614-8051-8_11. Adv Exp Med Biol. 2013. PMID: 24014300 Review.
Are all chimeric antigen receptors created equal?
Park JH, Brentjens RJ. Park JH, et al. J Clin Oncol. 2015 Feb 20;33(6):651-3. doi: 10.1200/JCO.2014.57.5472. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605860 No abstract available.
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Halton E, Lamanna N, Rademaker J, Sadelain M, Brentjens RJ, Park JH. Geyer MB, et al. Among authors: park jh. Mol Ther. 2018 Aug 1;26(8):1896-1905. doi: 10.1016/j.ymthe.2018.05.018. Epub 2018 Jun 15. Mol Ther. 2018. PMID: 29910179 Free PMC article. Clinical Trial.
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, van Leeuwen DG, Sadelain M, Park JH, Brentjens RJ. Geyer MB, et al. Among authors: park jh. JCI Insight. 2019 Apr 2;5(9):e122627. doi: 10.1172/jci.insight.122627. JCI Insight. 2019. PMID: 30938714 Free PMC article. Clinical Trial.
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.
Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, Manchini ST, George G, Shah N, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Park JH, Geyer MB, Zelenetz AD, Sauter CS, Giralt SA, Perales MA, Mato AR. Roeker LE, et al. Among authors: park jh. Blood Adv. 2020 Aug 25;4(16):3977-3989. doi: 10.1182/bloodadvances.2020001956. Blood Adv. 2020. PMID: 32841336 Free PMC article.
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Geyer MB, Ritchie EK, Rao AV, Vemuri S, Flynn J, Hsu M, Devlin SM, Roshal M, Gao Q, Shukla M, Salcedo JM, Maslak P, Tallman MS, Douer D, Park JH. Geyer MB, et al. Among authors: park jh. Haematologica. 2021 Aug 1;106(8):2086-2094. doi: 10.3324/haematol.2020.251686. Haematologica. 2021. PMID: 33054114 Free PMC article.
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
Advani AS, Moseley A, O'Dwyer KM, Wood BL, Fang M, Wieduwilt MJ, Aldoss I, Park JH, Klisovic RB, Baer MR, Stock W, Bhave RR, Othus M, Harvey RC, Willman CL, Litzow MR, Stone RM, Sharon E, Erba HP. Advani AS, et al. Among authors: park jh. J Clin Oncol. 2022 May 10;40(14):1574-1582. doi: 10.1200/JCO.21.01766. Epub 2022 Feb 14. J Clin Oncol. 2022. PMID: 35157496 Free PMC article. Clinical Trial.
15,439 results
You have reached the last available page of results. Please see the User Guide for more information.